Literature DB >> 22294323

The evaluation of surgical treatment for gastric cancer patients with noncurative resection.

Teiji Naka1, Makoto Iwahashi, Mikihito Nakamori, Masaki Nakamura, Toshiyasu Ojima, Takeshi Iida, Masahiro Katsuda, Tsuji Toshiaki, Hayata Keiji, Hiroki Yamaue.   

Abstract

PURPOSE: This study aims to analyze the results of treatment in a series of 233 gastric cancer patients who underwent a noncurative resection.
METHODS: We performed a retrospective study of patients with noncurative treatment for advanced gastric cancer who were divided into three treatment groups: total gastrectomy (TG, n=150), distal gastrectomy (DG, n=44), and nonresection (NR, bypass procedure or chemotherapy only, n=39).
RESULTS: In multivariate analysis, surgical treatment (TG) and an absence of chemotherapy were significant independent prognostic factors for a poor survival. In the late period, the overall survival rate was significantly lower in the TG group than in the DG group (p=0.005) and was marginally lower than in the NR group (p=0.054). The resection group had a poorer compliance for chemotherapy than the NR group, and the TG group had a poorer compliance than the DG group (p<0.01). The morbidity rate was higher in the TG group than in the DG group (p<0.05).
CONCLUSIONS: TG is considered to be inappropriate for the treatment of noncurative gastric cancer because of the poor prognosis, high morbidity rates, and poor compliance for chemotherapy associated with the procedure. However, noncurative DG was acceptable and postoperative chemotherapy should be used in selected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22294323     DOI: 10.1007/s00423-012-0906-z

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  31 in total

1.  Preoperative multivariate prediction of morbidity after gastrectomy for adenocarcinoma.

Authors:  L F Oñate-Ocaña; S A Cortés-Cárdenas; V Aiello-Crocifoglio; R Mondragón-Sánchez; J M Ruiz-Molina
Journal:  Ann Surg Oncol       Date:  2000-05       Impact factor: 5.344

2.  7th edition of the AJCC cancer staging manual: stomach.

Authors:  Kay Washington
Journal:  Ann Surg Oncol       Date:  2010-12       Impact factor: 5.344

3.  Clinical evaluation of hepatic arterial infusion of low dose-CDDP and 5-FU with hyperthermotherapy: a preliminary study for liver metastases from esophageal and gastric cancer.

Authors:  M Iwahashi; H Tanimura; M Nakamori; Y Nagai; N Hirabayashi; K Ueda; K Matsuda; T Tsunoda; H Yamaue
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

4.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

5.  Clinical benefit of palliative radiation therapy in advanced gastric cancer.

Authors:  Michelle M Kim; Vishal Rana; Nora A Janjan; Prajnan Das; Alexandria T Phan; Marc E Delclos; Paul F Mansfield; Jaffer A Ajani; Christopher H Crane; Sunil Krishnan
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

6.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

7.  Palliative gastrectomy and chemotherapy for stage IV gastric cancer.

Authors:  Sheng-Zhang Lin; Hong-Fei Tong; Tao You; Yao-Jun Yu; Wei-Jun Wu; Cong Chen; Wei Zhang; Bing Ye; Chun-Ming Li; Zhi-Qiang Zhen; Jia-Rong Xu; Jun-Liang Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-05       Impact factor: 4.553

8.  Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.

Authors:  Woo Young Kim; Bunzo Nakata; Kosei Hirakawa
Journal:  Cancer Sci       Date:  2007-08-07       Impact factor: 6.716

9.  Value of palliative resection in gastric cancer.

Authors:  H H Hartgrink; H Putter; E Klein Kranenbarg; J J Bonenkamp; C J H van de Velde
Journal:  Br J Surg       Date:  2002-11       Impact factor: 6.939

10.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  2 in total

1.  The Benefits of Resection for Gastric Carcinoma Patients with Non-curative Factors.

Authors:  Jae Hyuk Lee; Ho Gun Kim; Seong Yeob Ryu; Dong Yi Kim
Journal:  Chonnam Med J       Date:  2018-01-25

2.  Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.

Authors:  Joseph Cowling; Bethany Gorman; Afrah Riaz; James R Bundred; Sivesh K Kamarajah; Richard P T Evans; Pritam Singh; Ewen A Griffiths
Journal:  J Gastrointest Cancer       Date:  2020-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.